The key points
- The studio Com-Cov
- The results
- The answers that are still missing
Many countries are assuming different vaccine ranges by manufacturer, but also by type. If this were possible, in fact, vaccination campaigns could be further accelerated and administration protocols by type of population could be optimized. For example, boosters other than the AstraZeneca vaccine could be proposed in young women who have received Vaxzevria as their first dose, if only to reassure and convince more people to get vaccinated.
The studio Com-Cov
To this end, the University of Oxford launched the Com-Cov study at the beginning of 2021, in which assortments of Vaxzevria, Moderna, Novavax and Pfizer-BionTech were provided, both on (over a thousand) people who have already been vaccinated. with the first dose of Vaxzevria, both on (over 800) people who have not received any dose.
Loading…
The results
And now Lancet publishes the first available results: those on the safety of the assortment between Pfizer-BionTech and Vaxzevria in unvaccinated subjects. In both schemes, that is, both among those who received the first dose of Pfizer-BionTech then the second of Vaxzevria and vice versa, no elements of concern emerged. What is seen is only an increased frequency, always after the second dose, of short-term side effects such as fever, flu-like symptoms, headache, sore throat, fatigue, pain at the injection site and etc. This means that the mix is more reactogenic and could – but has yet to be proven – also be more immunogenic.
The answers that are still missing
It should also be remembered that the whole study was carried out on people over 50 and that therefore the assortment, given to young people, could provoke even more marked reactions, which could force people to lose a few days of work: an element of which must take into account especially when immunising subjects who work in places such as hospitals, to avoid staff shortages.Moreover, although the sample is significant, it does not allow – neither in size nor in timing – to have information on rarer events such as thrombosis. For these data as for those on the real effectiveness it will be necessary to wait a few more weeks.